{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:02Z","timestamp":1787013902218,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Currently, treatment for Alzheimer's disease (AD) focuses on the cholinergic hypothesis and provides limited symptomatic effects. Research currently focuses on other factors that are thought to contribute to AD development such as tau proteins and A\u03b2 deposits, and how modification of the associated pathology affects outcomes in patients. This systematic review summarizes and appraises the evidence for the emerging drugs affecting A\u03b2 and tau pathology in AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A comprehensive, systematic online database search was conducted using the databases ScienceDirect and PubMed to include original research articles. A systematic review was conducted following a minimum set of standards, as outlined by The PRISMA Group\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#bcp12621-bib-0001\"\/>\n                      . Specific inclusion and exclusion criteria were followed and studies fitting the criteria were selected. No human trials were included in this review.\n                      <jats:italic>In vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      AD models were used to assess efficacy to ensure studied agents were emerging targets without large bodies of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The majority of studies showed statistically significant improvement (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05) of A\u03b2 and\/or tau pathology, or cognitive effects. Many studies conducted in AD animal models have shown a reduction in A\u03b2 peptide burden and a reduction in tau phosphorylation post\u2010intervention. This has the potential to reduce plaque formation and neuronal degeneration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are many emerging targets showing promising results in the effort to modify the pathological effects associated with AD. Many of the trials also provided evidence of the clinical effects of such drugs reducing pathological outcomes, which was often demonstrated as an improvement of cognition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.12621","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T22:35:04Z","timestamp":1425594904000},"page":"221-234","source":"Crossref","is-referenced-by-count":47,"title":["Emerging drug targets for A\n                    <b>\u03b2<\/b>\n                    and tau in Alzheimer's disease: a systematic review"],"prefix":"10.1111","volume":"80","author":[{"given":"Sophie","family":"West","sequence":"first","affiliation":[{"name":"Sunderland Pharmacy School, Department of Pharmacy, Health and Wellbeing The University of Sunderland  City Campus, Chester Road Sunderland SR1 3SD United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Bhugra","sequence":"additional","affiliation":[{"name":"Sunderland Pharmacy School, Department of Pharmacy, Health and Wellbeing The University of Sunderland  City Campus, Chester Road Sunderland SR1 3SD United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"The PRISMA Group. Transparent reporting of systematic reviews and meta\u2010analyses 2009. Available athttp:\/\/www.prisma\u2010statement.org\/statement.htm(last accessed 3 April 2014)."},{"key":"e_1_2_9_3_1","unstructured":"Alzheimer's Society. Dementia 2013 Infographic 2014. Available athttp:\/\/www.alzheimers.org.uk\/infographic(last accessed 21 February 2014)."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.10.068"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2003"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.09.011"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2011.06.023"},{"key":"e_1_2_9_8_1","unstructured":"National Institute for Health and Care Excellence.Donepezil galantamine rivastigmine and memantine for the treatment of Alzheimer's disease 2011. Available athttp:\/\/publications.nice.org.uk\/donepezil\u2010galantamine\u2010rivastigmine\u2010and\u2010memantine\u2010for\u2010the\u2010treatment\u2010of\u2010alzheimers\u2010disease\u2010ta217(last accessed 4 April 2014)."},{"key":"e_1_2_9_9_1","unstructured":"KrauthD WoodruffT BeroL. A Systematic Review of Quality Assessment Tools for Published Animal Studies 2012. [Online Poster] Available athttp:\/\/2012.colloquium.cochrane.org\/sites\/2012.colloquium.cochrane.org\/files\/uploads\/posters\/126.pdf(last accessed 13 March 2014)."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.02.001"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.19"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720512800492459"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2013.08.001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0354-12.2012"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2012.07.006"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2013.09.001"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1350-13.2013"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.08.030"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.10.016"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.04.018"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2012.08.021"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.02.016"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.11.014"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017971"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.03.011"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2012.10.005"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.10.026"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.11.023"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.011"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2012.03.013"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.09.015"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.10.029"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.01.023"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2013.09.011"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2013.08.006"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.neurobiolaging.2013.08.030","article-title":"Melanocortins protect against progression of Alzheimer's disease in triple\u2010transgenic mice by targeting multiple pathophysiological pathways","volume":"35","author":"Giuliani D","year":"2014","journal-title":"Neurobiol Aging"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2013.10.038"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2012.09.013"},{"key":"e_1_2_9_39_1","first-page":"439","article-title":"Leptin regulates amyloid \u03b2 production via the \u03b3\u2010secretase complex","volume":"2013","author":"Niedowicz DM","year":"1832","journal-title":"Biochim Biophys Acta"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2012.12.023"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(84)90007-4"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12621","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:53:01Z","timestamp":1696301581000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/bcp.12621"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12621","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]}}}